The upcoming webinar will delve into the advanced applications of Next Generation Flow™ in the analysis of Minimal Residual Disease (MRD) in Multiple Myeloma (MM). Dr. Juan Flores-Montero, a ...

Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood 2005; 106 : 2276–2279. Article CAS Google Scholar ...

Advances in drugs and combinations have revolutionized the landscape in multiple myeloma, thus allowing patients to live much longer, according to Bruno Paiva, PhD, director of flow cytometry and ...

Measurable residual disease by Next-Generation flow cytometry in Multiple Myeloma. Paiva B, Puig N, Cedena MT, Rosiñol L, Cordón L, Vidriales MB, et al. 2020 J Clin Oncol. Mar 10;38(8):784-792 ...

Freeman explained that while traditional pathology techniques have a detection limit of about one in 100 cells, modern methods like next-generation flow cytometry and next-generation sequencing ...

In recent years, Measurable Residual Disease (MRD) assessment in Multiple Myeloma (MM) has gained increasing relevance. After more than a decade of active research in the field, new drugs and ...

Multiple myeloma can cause an increase in calcium called hypercalcemia. The tests also check kidney and liver function. Beta2-microglobulin ... This helps identify myeloma cells. Flow cytometry: ...

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study. JCO 31 , 2540-2547 (2013). DOI: ...

Advances in scientists' understanding of multiple myeloma ... /CT scans, and those focused on detecting intramedullary disease, either multiparameter flow cytometry (MFC) ...